Applied DNA Sciences, Inc. (APDN)
| Previous close | 1.3900 |
| Open | 1.3700 |
| Bid | 1.2800 x 1800 |
| Ask | 1.3400 x 1300 |
| Day's range | 1.2500 - 1.3900 |
| 52-week range | 1.0800 - 8.1000 |
| Volume | |
| Avg. volume | 66,591 |
| Market cap | 9.507M |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Applied DNA Reports Second Quarter Fiscal 2022 Financial Results
STONY BROOK, N.Y., May 12, 2022--Revenues at Record $6.2 Million, up 130% Year-over-Year; Cash at $6.5 Million Inclusive of Net Proceeds from Offering and Strong Cash Collections.
- Business Wire
Applied DNA Schedules Fiscal 2022 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 12, 2022
STONY BROOK, N.Y., May 09, 2022--Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in cell-free, enzymatic DNA production, today announced that it will report fiscal 2022 second quarter financial results after market close on Thursday, May 12, 2022. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘Company Events’ sub-page of the Comp
- Business Wire
Applied DNA Awarded NYC-Based ‘Return-to-Office’
STONY BROOK, N.Y., April 06, 2022--Applied DNA Clinical Labs secures NYC-based 'Return-to-Office' health services contract for COVID-19 testing.
